India Generics Market Summary, Competitive Analysis and Forecast to 2027

Key Highlights

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
• The Indian generics market had total revenues of $17.6 billion in 2022, representing a compound annual growth rate (CAGR) of 8.1% between 2017 and 2022.
• Market consumption volume increased with a CAGR of 0.4% between 2017 and 2022, to reach a total of 97.4% in 2022.
• The increasing number of cardiovascular and infectious diseases is boosting the demand for generic medicines across the country. According to the International Diabetes Federation, 77 million people in the country currently have diabetes, which is projected to reach 134 million by 2045.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in India
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in India
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the India generics market with five year forecasts

Reasons to Buy

• What was the size of the India generics market by value in 2022?
• What will be the size of the India generics market in 2027?
• What factors are affecting the strength of competition in the India generics market?
• How has the market performed over the last five years?
• What are the main segments that make up India's generics market?